Literature DB >> 12030340

Clinical significance of T-wave alternans in hypertrophic cardiomyopathy.

Nami Kuroda1, Yoshio Ohnishi, Akihiro Yoshida, Akinori Kimura, Mitsuhiro Yokoyama.   

Abstract

The clinical significance of T-wave alternans (TWA) in hypertrophic cardiomyopathy (HCM) is unclear, so SV1+RV5 and QT dispersion on 12-lead electrocardiograms (ECG), the parameters of the left ventricle on echocardiography and the family history of HCM and sudden death were investigated in 53 patients with HCM who experienced TWA. The maximal numbers of successive ventricular ectopic beats (max VE) and nonsustained ventricular tachycardia (NSVT) were measured by Holter monitoring. In 13 patients, genetic abnormalities were examined. In 22 patients, the hypertrophy of myocytes, disarray and fibrosis were histopathologically examined using a scoring method. TWA was positive in 27 patients (TWA+ group), negative in 14 (TWA- group) and indeterminate in 12. The ECG and echocardiographic parameters, family history and genetic abnormalities did not significantly differ between the TWA+ and TWA- groups. Max VE, the percentage of patients with NSVT and disarray score in the TWA+ group were significantly higher than those in the TWA- group (3.6+/-3.6 vs 1.3+/-0.7, 37% vs 0%, 1.9+/-1.1 vs 0.7+/-0.5; p<0.05). TWA in HCM correlates with histopathological changes, especially disarray and ventricular tachyarrhythmia, and measuring it may be a noninvasive means of detecting high-risk patients with HCM.

Entities:  

Mesh:

Year:  2002        PMID: 12030340     DOI: 10.1253/circj.66.457

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

Review 1.  T-wave alternans: reviewing the clinical performance, understanding limitations, characterizing methodologies.

Authors:  Euler de Vilhena Garcia
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-10       Impact factor: 1.468

2.  The prevalence and the prognostic value of microvolt T-wave alternans in patients with hypertrophic cardiomyopathy.

Authors:  Ewa Trzos; Jarosław D Kasprzak; Maria Krzemińska-Pakuła; Tomasz Rechciński; Karina Wierzbowska-Drabik; Barbara Uznańska; Adam Śmiałowski; Tomasz Rudziński; Małgorzata Kurpesa
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-07       Impact factor: 1.468

3.  Histologic characterization of hypertrophic cardiomyopathy with and without myofilament mutations.

Authors:  Christopher J McLeod; J Martijn Bos; Jeanne L Theis; William D Edwards; Bernard J Gersh; Steve R Ommen; Michael J Ackerman
Journal:  Am Heart J       Date:  2009-10-03       Impact factor: 4.749

4.  Distinct ECG Phenotypes Identified in Hypertrophic Cardiomyopathy Using Machine Learning Associate With Arrhythmic Risk Markers.

Authors:  Aurore Lyon; Rina Ariga; Ana Mincholé; Masliza Mahmod; Elizabeth Ormondroyd; Pablo Laguna; Nando de Freitas; Stefan Neubauer; Hugh Watkins; Blanca Rodriguez
Journal:  Front Physiol       Date:  2018-03-13       Impact factor: 4.566

5.  Microvolt QRS Alternans in Hypertrophic Cardiomyopathy: A Novel Risk Marker of Late Ventricular Arrhythmias.

Authors:  Praloy Chakraborty; Adrian M Suszko; Karthik Viswanathan; Kimia Sheikholeslami; Danna Spears; Arnon Adler; Anna Woo; Harry Rakowski; Vijay S Chauhan
Journal:  J Am Heart Assoc       Date:  2021-12-02       Impact factor: 5.501

6.  Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathy.

Authors:  Ingegerd Ostman-Smith; Aase Wisten; Eva Nylander; Ewa-Lena Bratt; Anne de-Wahl Granelli; Abderrahim Oulhaj; Erik Ljungström
Journal:  Eur Heart J       Date:  2009-11-05       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.